beta-1b (interferons) and natalizumab and the reactions suspected of being associated with them were identified. Disproportionality analyses used the Multi-item Poisson Gamma Shrinker method with WHO-ART diagnosis at the preferred term level for all AEs and for the standard combination of all WHO =critical terms=. Statistical significance for disproportionality was defined as an Empirical Bayesian Geometric Mean lower fifth percentile (EBGM05) Ͼ2.0. Comparisons were made between GA versus all other drugs and GA versus interferons and natalizumab. Sales data for GA were available to calculate reporting rates. RESULTS: A total of 2,320 cases with 6,680 AEs with a suspected relationship with GA and 20,155 cases with 72,326 AEs for interferons and natalizumab were identified. Compared with all other drugs in Vigibase and with interferons and natalizumab, GA was associated with several statistically significant observations of disproportionate reporting. WHO =critical terms= combined were not higher for GA versus interferons and natalizumab (EBGM of 0.84 (90% credibility interval 0.79-0.90). The reporting rate of WHO =critical terms= for GA was 69 events/100,000 person-year. CONCLUSIONS: In a risk-benefit analysis of GA based on traditional meta-analysis, the number of AEs in eligible controlled placebo/untreated and head-to-head studies were limited. In such a situation analysis of a global large spontaneous AEs database permitted the assessment of non-common and important risks. However, the biases inherent in these databases need to be addressed.
1
HERON Evidence Development Ltd, Luton, UK, 2 Biogen Idec, Weston, MA, USA, 3 Biogen Idec, Zug, Switzerland OBJECTIVES: Ambulation is the most highly valued bodily function for MS patients (Heesen et al.) , with ambulation problems recorded in up to 75% of patients (Hobart et al.) . Fampridine is a first-in-class treatment for ambulation. It improves the conductivity of the nerves where demyelination has occurred. A preliminary budget impact model (BIM) has been created to analyse the impact of introducing fampridine to treat MS patients with walking impairment in the UK market. METHODS: The BIM calculates the budget impact from a UK payer perspective of introducing fampridine in addition to usual care to an eligible MS patient population suffering from ambulation problems with an Expended Disability Severity Scale (EDSS) between 4 and 7.5, using a 3 year time horizon and a market forecast. The model conservatively assumes that all patients respond to treatment and there is no effect of fampridine on usual care resource use. A monthly withdrawal rate is also applied. RESULTS: The acquisition cost of fampridine is estimated at £3800 per patient per year. An approximate eligible population of 35,000 MS patients is estimated from literature. The market forecast estimates an uptake of 3%, 10% and 16% of the eligible population in the first three years respectively, and the estimated withdrawal rate is 2.2%. Compared to usual care alone, the annual results for the first three years show an additional budget of £3.4million, £10.9million and £18.2million respectively. CONCLUSIONS: The model presents conservative estimates whilst still showing a relatively low impact on the payer's budget, demonstrating that a major unmet need of MS patients can be met without a large increase in budget. Further research is required into response rates, effect of fampridine on usual care treatment costs to get a more accurate estimate of the impact fampridine. 
PND11 BUDGET IMPACT ANALYSIS OF FIRST-LINE TREATMENT FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

OBJECTIVES:
To assess the budget impact of the treatment for Relapsing Remitting Multiple Sclerosis (RRMS), interferons, and glatiramer acetate, from the National Health System (NHS) perspective. METHODS: A budget impact model was designed to compare the cost of RRMS treatment in different settings, using a 5 year timehorizon, considering different percentages of administration of each medication. A reference setting o base case using all the available first line treatments (interferons and glatiramer acetate) was compared with 5 alternatives scenarios excluding each one of these treatments. The cost analysis (2010 euros) includes direct medical resources (drugs, administration, visits, disease management, diagnostic tests). Unitary cost data was obtained from the health costs database e-Salud and drugs Catalogue. RESULTS: Considering a cohort of 22,255 patients with RRMS, the mean global budget impact per year would be € 260.775.470 in the base case. The setting that excluded glatiramer acetate increases the budget impact in a 3.23% (€ 372 per patient per year). Pharmacological costs were the key drivers of total cost (90%). CONCLUSIONS: The use of glatiramer acetate in the first-line-treatment of RRMS patients is a cost-saving strategy, which may decrease the budget impact from the NHS perspective in Spain. 
PND12 THE COST OF CORTICOSTEROID-ASSOCIATED ADVERSE EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS
OBJECTIVES:
To estimate costs of managing corticosteroid (CS)-related adverse events (AEs) within a systemic lupus erythematosus (SLE) population. METHODS: A retrospective claims analysis (January 1, 2000 -June 30, 2010) was conducted within an SLE population to evaluate the risk of known CS-related chronic and acute AEs among CS users and non-users by utilizing Cox proportional hazards models adjusting for patient characteristics, SLE severity, other SLE treatments, and AE-related risk factors. Associated costs were computed for AEs where the risk was significantly different among CS users compared to non-users. CS users having a chronic AE were followed for 12 months post-AE date to capture total costs, which were compared to total costs of CS users who did not have a chronic AE during the same time period. Predicted annual costs were generated using generalized linear models controlling for baseline characteristics. The incremental difference in annual costs among the two groups was considered attributable to the AE. For patients having an acute AE, disease-specific costs were calculated over a 12-month timeframe post-AE date. RESULTS: SLE patients receiving CS were more likely to develop chronic AEs (ie, cataracts, sleep disturbances, hypertension, type II diabetes, migraine) and acute AEs (ie, pneumonia, herpes zoster, fungal infections, nausea/vomiting). The average annual cost for managing AEs was highest for type II diabetes ($9763), followed by hypertension ($8774), sleep disturbances ($5599), migraine ($3591), cataracts ($2407), herpes zoster ($2079), pneumonia ($1726), nausea/ vomiting ($1357), and fungal infections ($857). When applying base rates and increased risk estimates of each AE to the cost estimates, it costs an additional $784/year per CS user to manage known CS-related AEs compared to CS non-users. CONCLUSIONS: Within an SLE population, CS treatment is associated with additional costs of $784/year due to management of CS-related AEs. Providers and payers should consider these potential costs of CS when making treatment decisions. OBJECTIVES: Approximately 50% of patients do not achieve seizure control with a single antiepileptic drug (AED). With the advent of multiple AEDs in the past 15 years, the choice of optimal polytherapy remains difficult in absence of clinical studies about the effectiveness of various combination therapies. This study aimed at describing the current management of focal epilepsy treated by polytherapy in France and at estimating the extra-costs of pharmacoresistance (PR) as redefined in 2009 by the International League Against Epilepsy (ILAE). METHODS: ESPERA is a European multicenter, observational, cross-sectional study conducted in France and Spain in 2010. A random sample of neurologists enrolled prospectively a sample of adult patients treated with at least two antiepileptic drugs (AEDs) in combination for focal epilepsy. The investigators classified their patients according to the new ILAE criteria and this classification was then reviewed by two independent experts. All items of medical resources use associated with epilepsy were collected retrospectively over the last year and valued according to a societal perspective. RESULTS: Seventy-one French neurologists collected analysable data on 405 patients. After review by experts, patients were finally classified as PR in 286 (70.6%) of them, in 91 (22.4%) as responsive and in 28 (7%) as undefined. The mean annual epilepsy related direct costs par patient were 4238 € (SD: 3772) in PR patients as compared with 1907€ (SD: 1,739) in responsive patients. AEDs costs were estimated 2602€ and 1544€ respectively and PR patients were significantly more often hospitalized (mean annual cost: 1023€ versus 78€) and had more procedures (mean annual cost: 194€ versus 53€). CONCLUSIONS: Despite the number of therapeutic alternatives available in epileptic patients, a large proportion of them remain with uncontrolled seizures yielding to significant extra costs. In addition, sensitivity of each strategy was calculated. Unless there are differences between unit cost along communities, the same unit cost source for all programs was used, in order to allow comparisons. RESULTS: The estimated EC per screened neonate were € 3.67, € 4.07, € 4.11 for TIR/ADN, TIR/ADN/DGGE, and TIR/ TIR/ADN respectively, showing that TIR/ADN/DGGE is the strategy with lowest EC for its population. Regarding the sensitivity of the three strategies, the results showed similar and high values for all of them, being the strategy of Basque Country which had highest value (99.37%). The ECs per neonate suffering CF were 82.703,48 €, 18.726,29 €, 16.604,10 € for TIR/ADN, TIR/ADN/DGGE, and TIR/TIR/ADN respectively, showing highest cost per neonate with the disease, however the power of this results is still low, and there are differences between incidences along strategies. CONCLUSIONS: In this cost comparative study it was obtained that the A319 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
PND13
MANAGEMENT OF FOCAL EPILEPSY TREATED BY POLYTHERAPY IN FRANCE: THE COST OF PHARMACO-RESISTANCE
PND14 COMPARING EXPECTED COSTS ASSOCIATED WITH THREE SCREENING STRATEGIES FOR CYSTIC FIBROSIS ALONG SPAIN
